Lung Cancer 2015-11-01

Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.

Jung-Min Choi, Ji-Young Jang, Yu-Ra Choi, Hye Ryun Kim, Byoung Chul Cho, Han-Woong Lee

Index: Lung Cancer 90 , 175-81, (2015)

Full Text: HTML

Abstract

Lung cancer is the commonly diagnosed cancer and is the leading cause of cancer-related mortality worldwide. The most prevalent form of lung cancer is NSCLC, comprising 80% of all lung cancer cases, and epidermal growth factor receptor (EGFR) is frequently mutated in NSCLC. EI24 is a p53-responsive gene and plays an important role in tumor suppression. In the current study, we found that reduced expression of EI24 conferred resistance to EGFR-tyrosine-kinase inhibitor (TKI) in NSCLC cells.The correlation between EI24 expression and EGFR-TKI drug resistance in EGFR-driven tumors were determined from microarray datasets. The phospho-protein expression profiles of receptor tyrosine kinases and protein kinases were examined using antibody arrays method in PC9 cells expressing shRNAs targeting EI24 and gefitinib-resistant PC9-GR cells expressing exogenous EI24.The EGFR-TKI resistant clones had reduced expression of EI24 mRNA compared to the sensitive clones, and EI24 knockdown rendered sensitive cells resistant to EGFR-TKI. Receptor tyrosine kinase screening revealed the involvement of a kinase switch in EI24-mediated regulation of drug sensitivity. We found that EI24 modulates the insulin growth factor-1 receptor (IGF-1R) pathway through the induction of IGF-1. Combination treatment with EGFR and IGF-1R inhibitors significantly reduced the viability of EI24 knockdown-induced resistant cell lines compared to single-agent treatments. We also showed that low EI24 and high IGF-1R expressions in lung cancer patients were correlated with reduced overall survival. Taken together, these results suggest a potential role for EI24 as a biomarker of drug resistance, and indicate that combination therapy with EGFR and IGF-1R inhibitors would be effective in NSCLC patients with low EI24 expression.Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.


Related Compounds

  • PQ 401

Related Articles:

Identification of Novel IGF1R Kinase Inhibitors by Molecular Modeling and High-Throughput Screening.

2013-04-01

[Acta Naturae 5(2) , 90-9, (2013)]

IGFBP-2 directly stimulates osteoblast differentiation.

2014-11-01

[J. Bone Miner Res. 29(11) , 2427-38, (2014)]

Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.

2006-04-01

[Mol. Cancer Ther. 5 , 1079-1086, (2006)]

Transcriptome sequencing identifies ETV6-NTRK3 as a gene fusion involved in GIST.

2016-03-01

[J. Pathol. 238 , 543-9, (2016)]

PQ401, an IGF-1R inhibitor, induces apoptosis and inhibits growth, proliferation and migration of glioma cells.

2016-01-01

[J. Chemother. 28 , 44-9, (2016)]

More Articles...